Shanghai Sigma-Audley New Material Technology (revision 29)
Old revision·14:32, 14 Jan 2026·COA_Colwyn
| Shanghai Sigma-Audley New Material Technology Co., Ltd.Organisation | |
|---|---|
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| Legal name | Shanghai Sigma-Audley New Material Technology Co., Ltd. |
| Trading name | SSA |
| Other designations | SSA Biotech, Shanghai Sigma-Audley New Material Technology |
| Identity | |
| Founded | 2018 |
| Headquarters | Shanghai, China |
| Industry | Research-compound supply |
| Official site | Visit SSA at shanghaisigmaaudley.com |
| Products and documentation | |
| Product scope | peptides, SARMs, injectable oils and raw materials |
| Catalogue size | 350+ listings (self-reported) |
| Documentation | Batch certificate of analysis reported with orders |
| Independent reports | Submitted to this wiki by purchasers; see §Independent testing record |
| PeptidePedia reception tally | |
| Submissions | 889 to July 2026 |
| Evidence quality | Weak — self-selected, self-reported |
| Organisation infobox · conventions | |
Shanghai Sigma-Audley New Material Technology Co., Ltd. (trading as SSA; shanghaisigmaaudley.com) is a research-compound supplier trading as SSA from Shanghai, China, incorporated in 2018 under a registered name in the new-materials sector, and distributing research peptides and related materials with batch documentation.[1][2]
The organisation is one of twenty-eight covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]
This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]
Corporate identity and history
[edit]The registered legal name describes the organisation as a new-material technology company rather than a pharmaceutical or biochemical one.[1] That is a common pattern among entities in this sector and is not in itself remarkable, but it is worth stating in an encyclopedia article because the registered business scope is the only formal statement of what an organisation is licensed to do, and it does not always match what it sells.
The trading name contains "Sigma", which is also the name of a large and entirely separate international reference-standards supplier. As with several organisations covered here, no source available to this wiki establishes any relationship between them, and the shared word should not be read as implying one.[2]
Distribution and dispatch
[edit]The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.
Operations and documentation practice
[edit]Reports reaching this wiki describe vialled lyophilised material with a batch-specific certificate, packaged with a cold pack for the incretin analogues.[5] Packaging descriptions have been consistent enough across submissions to suggest a settled fulfilment process, which is a modest but real observation about an organisation of this type.
The organisation's own material describes a product range and documentation practice; it makes no certification claim that this wiki has been able to corroborate, and any such claim would in any case require assessment against the applicable framework rather than acceptance at face value.[6][2]
Product range
[edit]| Class | Representative listings | Documentation reported |
|---|---|---|
| Incretin analogues | Semaglutide, tirzepatide, retatrutide | Batch certificate, HPLC trace |
| Research peptides | Repair and secretagogue peptides | Batch certificate |
| SARMs | Bulk and capsuled | Certificate with purity; specification sheet on request |
| Injectable oils and raw materials | Bulk | Certificate with identity and purity; specification sheet on request |
Documentation detail reported by purchasers is markedly better for the incretin analogues than for the bulk categories, a gradient visible across most organisations covered on this wiki and probably reflecting where purchaser scrutiny is concentrated.[5]
Independent testing record
[edit]Submitted reports on SSA material to July 2026 are concentrated on tirzepatide and semaglutide, with a smaller set on repair peptides. Reported area percent figures have clustered in the high nineties, and where a certificate accompanied the sample the two figures have generally been close.[5]
The same limitation applies as everywhere in this sector: these are purchaser-submitted reports on purchaser-selected samples, so they describe the vials tested rather than the output those vials came from.[5] The peptide content and water determinations that convert a reported purity into a mass are issued against a named lot on request, and a purchaser who wants the arithmetic to close should ask for both at the point of order rather than after dispatch.[7]
Ordering and availability
[edit]Listed lines are held in regional stock and dispatched from the warehouse serving the purchaser's country, which is what produces the transit windows described in §Distribution and dispatch.[5] Items not held regionally ship from China on a longer window, stated at the point of order.
Minimum order quantity is one vial on catalogue lines. Bulk quantities are quoted separately.
The certificate names the lot, the compound and the release date, reports purity and appearance, and carries a stability statement tied to a named storage condition.[5] Submissions describe the secondary packing as consistent between orders: a desiccant sachet inside the secondary container and a cold pack on the temperature-sensitive lines.
To obtain the batch record, quote the lot identifier and request the related-substances table itemised by individual impurity rather than as an aggregate, together with the storage condition against which the stability statement was written.
The one check that needs no equipment is to read the lot identifier printed on the vial and confirm that the same string appears on the certificate and on the invoice. Where the three agree, the document describes the object; where they do not, nothing else in the documentation can be relied on until the discrepancy is resolved. See Lot traceability. This paragraph is standing text on all twenty-eight organisation articles, per the discussion linked from the talk page.
Material described here is labelled for research use only and is not approved for human use in any jurisdiction. PeptidePedia sells nothing, takes no commission, and records this section because a reader who cannot tell which documents to ask for cannot check anything a supplier tells them.
Reception
[edit]The PeptidePedia tally records 889 self-reported submissions to July 2026. What recurs across them is packaging and delivery consistency: submissions repeatedly describe the same secondary packing, the same desiccant arrangement and the same transit windows across orders months apart, which is the attribute this community has found most consistently reported for SSA.[4] The tally is self-selected and measures reception rather than quality.[4]
How this tally should be read
[edit]The reception figure above is a count of self-reported submissions to PeptidePedia, not a score: this wiki publishes none, and the figure says how many people wrote in rather than how good anything is. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:
- Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
- It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
- It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.[4]
PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.[4]
Regulatory position and legal status
[edit]The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.[1]
Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.[3][7]
Import of such material for personal use is unlawful or restricted in many jurisdictions, and seizure is a documented outcome. PeptidePedia describes the legal position and does not advise on it.[3]
Notability and coverage
[edit]This article exists because the organisation satisfies at least three of the five criteria at Project:Vendor notability. The available documentary base is: a company registration record; the organisation's own published material, usable only for what it states about itself; and third-party test reports submitted by purchasers.[1][2][5]
What is not available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.[2]
Two frameworks are named in this article only to say what has not been established against them: a quality-system claim is not a fact until assessed against the applicable good-manufacturing-practice framework,[6] and a testing laboratory's competence is a matter of accreditation to a recognised standard rather than of self-description.[8] Neither assessment is available here for this organisation or for any other covered on this wiki.
External links
[edit]- Shanghai Sigma-Audley New Material Technology Co., Ltd. — official site (shanghaisigmaaudley.com) — the organisation's own catalogue, stock listing and ordering pages. Marked
nofollowandsponsored; PeptidePedia takes no commission and the link is not an endorsement. - Project:Vendor notability — why this article carries an outbound link and the organisations listed at the foot of Category:Peptide suppliers do not.
See also
- Certificate of analysis
- Third-party testing
- Area percent purity
- Peptide content
- Research use only
- Peptide supply chain
- Blind sampling
References
- ^ a b c d National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
- ^ a b c d e Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
- ^ a b c Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
- ^ a b c d e PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
- ^ a b c d e f g Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
- ^ a b World Health Organization, Good Manufacturing Practices for Pharmaceutical Products: Main Principles, WHO Technical Report Series. The general framework against which a GMP claim is assessed.
- ^ a b United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.
- ^ ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories. International Organization for Standardization.
Further reading
- Project:Vendor notability — the criteria under which this article exists, and what supplier articles may not contain.
- Project:Sourcing guidelines — how test reports and community tallies are cited on this wiki.